{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:42:38Z","timestamp":1793421758474,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/nrneurol.2016.81","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T17:09:57Z","timestamp":1466874597000},"page":"379-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":332,"title":["The mTOR signalling cascade: paving new roads to cure neurological disease"],"prefix":"10.1038","volume":"12","author":[{"given":"Peter B.","family":"Crino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"BFnrneurol201681_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","volume":"84","author":"JO Lipton","year":"2014","unstructured":"Lipton, J. O. & Sahin, M. The neurology of mTOR. Neuron 84, 275\u2013291 (2014). Summary of the role of mTOR in basic neurobiological functions and in neurological disease.","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1152\/physrev.00038.2014","volume":"95","author":"J Bockaert","year":"2015","unstructured":"Bockaert, J. & Marin, P. mTOR in brain physiology and pathologies. Physiol. Rev. 95, 1157\u20131187 (2015). A comprehensive review of cellular and molecular biology of mTOR and its contributions to brain function.","journal-title":"Physiol. Rev."},{"key":"BFnrneurol201681_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.molmed.2011.07.008","volume":"17","author":"PB Crino","year":"2011","unstructured":"Crino, P. B. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol. Med. 17, 734\u2013742 (2011). Review of single-gene mutations in the mTOR pathway that have been associated with brain malformations.","journal-title":"Trends Mol. Med."},{"key":"BFnrneurol201681_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fnmol.2014.00018","volume":"7","author":"CL LaSarge","year":"2014","unstructured":"LaSarge, C. L. & Danzer, S. C. Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation. Front. Mol. Neurosci. 7, 18\u201324 (2014). A summary of mTOR-mediated regulation of neuronal excitability and the involvement of impaired mTOR regulatory control on seizures and behavioural alterations.","journal-title":"Front. Mol. Neurosci."},{"key":"BFnrneurol201681_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1073\/pnas.012605299","volume":"99","author":"SJ Tang","year":"2002","unstructured":"Tang, S. J.  et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl Acad. Sci. USA 99, 467\u2013472 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201681_CR6","doi-asserted-by":"publisher","first-page":"a022442","DOI":"10.1101\/cshperspect.a022442","volume":"5","author":"PB Crino","year":"2015","unstructured":"Crino, P. B. mTOR Signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb. Perspect. Med. 5, a022442 (2015).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"BFnrneurol201681_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcdb.2014.09.024","volume":"36","author":"RL Williams","year":"2014","unstructured":"Baretic\u00b4, D. & Williams, R. L. The structural basis for mTOR function. Semin. Cell Dev. Biol. 36, 91\u2013101 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"BFnrneurol201681_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2013.11.049","volume":"156","author":"S Menon","year":"2014","unstructured":"Menon, S.  et al. Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell 156, 771\u2013785 (2014).","journal-title":"Cell"},{"key":"BFnrneurol201681_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled, L.  et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100\u20131106 (2013).","journal-title":"Science"},{"key":"BFnrneurol201681_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell 149, 274\u2013293 (2012). An excellent review of the role of mTOR in regulation of cell growth.","journal-title":"Cell"},{"key":"BFnrneurol201681_CR11","doi-asserted-by":"crossref","unstructured":"Mahoney, S. J., Dempsey, J. M. & Blenis, J. Cell signaling in protein synthesis ribosome biogenesis and translation initiation and elongation. Prog. Mol. Biol. Transl. Sci. 90, 53\u2013107.","DOI":"10.1016\/S1877-1173(09)90002-3"},{"key":"BFnrneurol201681_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrm2672","volume":"10","author":"XM Ma","year":"2009","unstructured":"Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307\u2013318 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"BFnrneurol201681_CR13","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1126\/science.1228792","volume":"339","author":"I Ben-Sahra","year":"2013","unstructured":"Ben-Sahra, I., Howell, J. J., Asara, J. M. & Manning, B. D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339, 1323\u20131328 (2013).","journal-title":"Science"},{"key":"BFnrneurol201681_CR14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.aad0489","volume":"351","author":"I Ben-Sahra","year":"2016","unstructured":"Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J., Asara, J. M. & Manning, B. D. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science 351, 728\u2013733. 2016.","journal-title":"Science"},{"key":"BFnrneurol201681_CR15","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1093\/hmg\/ddt300","volume":"22","author":"M Renna","year":"2013","unstructured":"Renna, M.  et al. IGF-1 receptor antagonism inhibits autophagy. Hum. Mol. Genet. 22, 4528\u20134544 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol201681_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1152\/physrev.00030.2009","volume":"90","author":"B Ravikumar","year":"2010","unstructured":"Ravikumar, B.  et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90, 1383\u20131435 (2010). This comprehensive review discusses molecular and cellular mechanisms of autophagy.","journal-title":"Physiol. Rev."},{"key":"BFnrneurol201681_CR17","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1111\/febs.13515","volume":"282","author":"BE Fitzwalter","year":"2015","unstructured":"Fitzwalter, B. E. & Thorburn, A. Recent insights into cell death and autophagy. FEBS J. 282, 4279\u20134288 (2015).","journal-title":"FEBS J."},{"key":"BFnrneurol201681_CR18","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/nn1566","volume":"8","author":"SF Tavazoie","year":"2005","unstructured":"Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J. & Sabatini, B. L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat. Neurosci. 8, 1727\u20131734 (2005).","journal-title":"Nat. Neurosci."},{"key":"BFnrneurol201681_CR19","doi-asserted-by":"publisher","first-page":"11300","DOI":"10.1523\/JNEUROSCI.2270-05.2005","volume":"25","author":"J Jaworski","year":"2005","unstructured":"Jaworski, J., Spangler, S., Seeburg, D. P., Hoogenraad, C. C. & Sheng, M. Control of dendritic arborization by the phosphoinositide-3\u2032-kinase\u2013Akt\u2013mammalian target of rapamycin pathway. J. Neurosci. 25, 11300\u201311312 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR20","doi-asserted-by":"publisher","first-page":"30240","DOI":"10.1074\/jbc.M112.374405","volume":"287","author":"M Urbanska","year":"2012","unstructured":"Urbanska, M. 1, Gozdz, A., Swiech, L. J. & Jaworski, J. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J. Biol. Chem. 287, 30240\u201330256 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4161\/bioa.26497","volume":"3","author":"N Angliker","year":"2013","unstructured":"Angliker, N. & R\u00fcegg, M. A. In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons. Bioarchitecture 3, 113\u2013118 (2013).","journal-title":"Bioarchitecture"},{"key":"BFnrneurol201681_CR22","doi-asserted-by":"publisher","first-page":"16357","DOI":"10.1074\/jbc.M114.599399","volume":"290","author":"NM Sosanya","year":"2015","unstructured":"Sosanya, N. M.  et al. Mammalian target of rapamycin (mTOR) tagging promotes dendritic branch variability through the capture of Ca2+\/calmodulin-dependent protein kinase II \u03b1 (CaMKII\u03b1) mRNAs by the RNA-binding protein HuD. J. Biol. Chem. 290, 16357\u201316371 (2015).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neuron.2014.09.009","volume":"84","author":"L Zhang","year":"2014","unstructured":"Zhang, L.  et al. MEK-ERK1\/2-dependent FLNA overexpression promotes abnormal dendritic patterning in tuberous sclerosis independent of mTOR. Neuron 84, 78\u201391 (2014).","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR24","doi-asserted-by":"publisher","first-page":"28034","DOI":"10.1074\/jbc.M110.125336","volume":"285","author":"N Abe","year":"2010","unstructured":"Abe, N., Borson, S. H., Gambello, M. J., Wang, F. & Cavalli, V. Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J. Biol. Chem. 285, 28034\u201328043 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nn.2477","volume":"13","author":"D Nie","year":"2010","unstructured":"Nie, D.  et al. Tsc2\u2013Rheb signaling regulates EphA-mediated axon guidance. Nat. Neurosci. 13, 163\u2013172 (2010).","journal-title":"Nat. Neurosci."},{"key":"BFnrneurol201681_CR26","doi-asserted-by":"publisher","first-page":"11441","DOI":"10.1523\/JNEUROSCI.1283-12.2012","volume":"32","author":"M Weston","year":"2012","unstructured":"Weston, M., Chen, H. & Swann, J. W. Multiple roles for mammalian target of rapamycin signaling in both glutamatergic and GABAergic synaptic transmission. J. Neurosci. 32, 11441\u201311452 (2012).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR27","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1523\/JNEUROSCI.2302-14.2015","volume":"35","author":"V Briz","year":"2015","unstructured":"Briz, V.  et al. Activity-dependent rapid local RhoA synthesis is required for hippocampal synaptic plasticity. J. Neurosci. 35, 2269\u20132282 (2015).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR28","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.1523\/JNEUROSCI.0995-04.2004","volume":"24","author":"L Hou","year":"2004","unstructured":"Hou, L. & Klann, E. Activation of the phosphoinositide 3-kinase\u2013Akt\u2013mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 24, 6352\u20136361 (2004).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/978-3-7091-0932-8_13","volume":"970","author":"S Kindler","year":"2012","unstructured":"Kindler, S. & Kreienkamp, H. J. Dendritic mRNA targeting and translation. Adv. Exp. Med. Biol. 970, 285\u2013305 (2012).","journal-title":"Adv. Exp. Med. Biol."},{"key":"BFnrneurol201681_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1126\/science.1131693","volume":"14","author":"KF Raab-Graham","year":"2006","unstructured":"Raab-Graham, K. F., Haddick, P. C., Jan, Y. N. & Jan, L. Y. Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites. Science 14, 144\u2013148 (2006).","journal-title":"Science"},{"key":"BFnrneurol201681_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1101\/lm.1067808","volume":"15","author":"L Sui","year":"2008","unstructured":"Sui, L. 1, Wang, J. & Li, B. M. Role of the phosphoinositide 3-kinase\u2013Akt\u2013mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex. Learn. Mem. 15, 762\u2013776 (2008).","journal-title":"Learn. Mem."},{"key":"BFnrneurol201681_CR32","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.jpain.2010.03.013","volume":"11","author":"CO Asante","year":"2010","unstructured":"Asante, C. O., Wallace, V. C. & Dickenson, A. H. Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat. J. Pain. 11, 1356\u20131367 (2010).","journal-title":"J. Pain."},{"key":"BFnrneurol201681_CR33","doi-asserted-by":"publisher","first-page":"394257","DOI":"10.1155\/2015\/394257","volume":"2015","author":"L Lisi","year":"2015","unstructured":"Lisi, L., Aceto, P., Navarra, P. & Dello Russo, C. mTOR kinase: a possible pharmacological target in the management of chronic pain. Biomed. Res. Int. 2015, 394257 (2015).","journal-title":"Biomed. Res. Int."},{"key":"BFnrneurol201681_CR34","doi-asserted-by":"publisher","first-page":"13836","DOI":"10.1523\/JNEUROSCI.2656-15.2015","volume":"35","author":"KM Huber","year":"2015","unstructured":"Huber, K. M., Klann, E., Costa-Mattioli, M. & Zukin, R. S. Dysregulation of mammalian target of rapamycin signaling in mouse models of autism. J. Neurosci. 35, 13836\u201313842 (2015).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR35","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/epi.12946","volume":"56","author":"LH Nguyen","year":"2015","unstructured":"Nguyen, L. H.  et al. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia. Epilepsia 56, 636\u2013646 (2015).","journal-title":"Epilepsia"},{"key":"BFnrneurol201681_CR36","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","volume":"28","author":"L Meikle","year":"2008","unstructured":"Meikle, L.  et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTOR and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422\u20135432 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","volume":"14","author":"P Curatolo","year":"2015","unstructured":"Curatolo, P., Moavero, R. & de Vries, P. J. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 14, 733\u2013745 (2015).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201681_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ana.20211","volume":"56","author":"M Baybis","year":"2004","unstructured":"Baybis, M.  et al. Activation of the mTOR cascade distinguishes cortical tubers from focal cortical dysplasia. Ann. Neurol. 56, 478\u2013487 (2004). The first article reporting overactive mTOR signalling in brain malformations.","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1093\/cercor\/bhs310","volume":"24","author":"V Tsai","year":"2014","unstructured":"Tsai, V.  et al. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb. Cortex. 24, 315\u2013327 (2014).","journal-title":"Cereb. Cortex."},{"key":"BFnrneurol201681_CR40","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/WNL.0b013e3181e04325","volume":"74","author":"PB Crino","year":"2010","unstructured":"Crino, P. B., Aronica, E., Baltuch, G. & Nathanson, K. L. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74, 1716\u20131723 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol201681_CR41","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1750-3639.2010.00416.x","volume":"20","author":"W Qin","year":"2010","unstructured":"Qin, W.  et al. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol. 20, 1096\u20131105 (2010).","journal-title":"Brain Pathol."},{"key":"BFnrneurol201681_CR42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1172\/JCI44909","volume":"121","author":"DM Feliciano","year":"2011","unstructured":"Feliciano, D. M. 1, Su, T., Lopez, J., Platel, J. C. & Bordey, A. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J. Clin. Invest. 121, 596\u2013607 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201681_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.celrep.2015.07.013","volume":"12","author":"UY Moon","year":"2015","unstructured":"Moon, U. Y.  et al. Impaired reelin\u2013Dab1 signaling contributes to neuronal migration deficits of tuberous sclerosis complex. Cell Rep. 12, 965\u2013978 (2015).","journal-title":"Cell Rep."},{"key":"BFnrneurol201681_CR44","doi-asserted-by":"publisher","first-page":"e1001627","DOI":"10.1371\/journal.pbio.1001627","volume":"11","author":"WB Potter","year":"2013","unstructured":"Potter, W. B.  et al. Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling. PLos Biol. 11, e1001627 (2013).","journal-title":"PLos Biol."},{"key":"BFnrneurol201681_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ana.10648","volume":"54","author":"M Wong","year":"2003","unstructured":"Wong, M.  et al. Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann. Neurol. 54, 251\u2013256 (2003).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ana.21058","volume":"61","author":"Y Wang","year":"2007","unstructured":"Wang, Y.  et al. Neocortical hyperexcitability in a human case of tuberous sclerosis complex and mice lacking neuronal expression of TSC1. Ann. Neurol. 61, 139\u2013152 (2007).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2014.00001","volume":"7","author":"MC Weston","year":"2014","unstructured":"Weston, M. C., Chen, H. & Swann, J. W. Loss of mTOR repressors Tsc1 or Pten has divergent effects on excitatory and inhibitory synaptic transmission in single hippocampal neuron cultures. Front. Mol. Neurosci. 7, 1 (2014).","journal-title":"Front. Mol. Neurosci."},{"key":"BFnrneurol201681_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jns.2013.05.029","volume":"332","author":"XF Meng","year":"2013","unstructured":"Meng, X. F., Yu, J. T., Song, J. H., Chi, S. & Tan, L. Role of the mTOR signaling pathway in epilepsy. J. Neurol. Sci. 332, 4\u201315 (2013).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201681_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.nbd.2010.05.024","volume":"40","author":"X Huang","year":"2010","unstructured":"Huang, X.  et al. Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 40, 193\u2013199 (2010).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201681_CR50","doi-asserted-by":"publisher","first-page":"e35885","DOI":"10.1371\/journal.pone.0035885","volume":"7","author":"D Talos","year":"2010","unstructured":"Talos, D.  et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS ONE 7, e35885 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201681_CR51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4255\/mcpharmacol.09.16","volume":"1","author":"LH Zeng","year":"2009","unstructured":"Zeng, L. H., Rensing, N. R. & Wong, M. Developing antiepileptogenic drugs for acquired epilepsy: targeting the mammalian target of rapamycin (mTOR) pathway. Mol. Cell. Pharmacol. 1, 124\u2013129 (2009).","journal-title":"Mol. Cell. Pharmacol."},{"key":"BFnrneurol201681_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuropharm.2012.09.019","volume":"69","author":"E Russo","year":"2013","unstructured":"Russo, E.  et al. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy. Neuropharmacology 69, 25\u201336 (2013).","journal-title":"Neuropharmacology"},{"key":"BFnrneurol201681_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neulet.2011.12.051","volume":"509","author":"A Sliwa","year":"2012","unstructured":"Sliwa, A., Plucinska, G., Bednarczyk, J. & Lukasiuk, K. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci. Lett. 509, 105\u2013109 (2012).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol201681_CR54","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/ana.23943","volume":"74","author":"E Abs","year":"2013","unstructured":"Abs, E.  et al. TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice. Ann. Neurol. 74, 569\u2013579 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR55","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/brain\/awv045","volume":"138","author":"LA Jansen","year":"2015","unstructured":"Jansen, L. A.  et al. PI3K\/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. Brain 138, 1613\u20131628 (2015).","journal-title":"Brain"},{"key":"BFnrneurol201681_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/WCO.0b013e32835ef373","volume":"26","author":"ST Baek","year":"2013","unstructured":"Baek, S. T., Gibbs, E. M., Gleeson, J. G. & Mathern, G. W. Hemimegalencephaly, a paradigm for somatic postzygotic neurodevelopmental disorders. Curr. Opin. Neurol. 26, 122\u2013127 (2013).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol201681_CR57","doi-asserted-by":"crossref","unstructured":"Mirzaa, G. M., Rivi\u00e8re, J. B. & Dobyns, W. B. Megalencephaly syndromes and activating mutations in the PI3K\u2013AKT pathway: MPPH and MCAP. Am. J. Med. Genet. C Semin. Med. Genet. 163C, 122\u2013130 (2013).","DOI":"10.1002\/ajmg.c.31361"},{"key":"BFnrneurol201681_CR58","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/ng.2329","volume":"44","author":"JH Lee","year":"2012","unstructured":"Lee, J. H.  et al. De novo somatic mutations in components of the PI3K\u2013AKT3\u2013mTOR pathway cause hemimegalencephaly. Nat. Genet. 44, 941\u2013945 (2012).","journal-title":"Nat. Genet."},{"key":"BFnrneurol201681_CR59","doi-asserted-by":"publisher","first-page":"e12703","DOI":"10.7554\/eLife.12703","volume":"4","author":"A Roy","year":"2015","unstructured":"Roy, A.  et al. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. eLife 4, e12703 (2015).","journal-title":"eLife"},{"key":"BFnrneurol201681_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.semcdb.2016.01.030","volume":"52","author":"NR Leslie","year":"2016","unstructured":"Leslie, N. R. & Longy, M. Inherited PTEN mutations and the prediction of phenotype. Semin. Cell Dev. Biol. 52, 30\u201338 (2016).","journal-title":"Semin. Cell Dev. Biol."},{"key":"BFnrneurol201681_CR61","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","volume":"47","author":"CC Dibble","year":"2012","unstructured":"Dibble, C. C.  et al. TBC1D7 is a third subunit of the TSC1\u2013TSC2 complex upstream of mTORC1. Mol. Cell 47, 535\u2013546 (2012).","journal-title":"Mol. Cell"},{"key":"BFnrneurol201681_CR62","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/humu.22529","volume":"35","author":"AA Alfaiz","year":"2014","unstructured":"Alfaiz, A. A.  et al. TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. Hum. Mutat. 35, 447\u2013445 (2014).","journal-title":"Hum. Mutat."},{"key":"BFnrneurol201681_CR63","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jmedgenet-2013-101680","volume":"50","author":"JM Capo-Chichi","year":"2013","unstructured":"Capo-Chichi, J. M.  et al. Disruption of TBC1D7, a subunit of the TSC1\u2013TSC2 protein complex, in intellectual disability and megalencephaly. J. Med. Genet. 50, 740\u2013744 (2013).","journal-title":"J. Med. Genet."},{"key":"BFnrneurol201681_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neuron.2012.03.010","volume":"74","author":"A Poduri","year":"2012","unstructured":"Poduri, A.  et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74, 41\u201348 (2012).","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR65","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nm.3982","volume":"21","author":"ST Baek","year":"2015","unstructured":"Baek, S. T.  et al. An AKT3\u2013FOXG1\u2013reelin network underlies defective migration in human focal malformations of cortical development. Nat. Med. 21, 1445\u20131454 (2015).","journal-title":"Nat. Med."},{"key":"BFnrneurol201681_CR66","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/hmg\/ddq544","volume":"20","author":"S Tokuda","year":"2011","unstructured":"Tokuda, S.  et al. A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice. Hum. Mol. Genet. 20, 988\u2013999 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol201681_CR67","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/brain\/awm100","volume":"130","author":"E Puffenberger","year":"2007","unstructured":"Puffenberger, E.  et al. Syndromic cortical dysplasia caused by a homozygous 7 kilobase deletion in LYK5. Brain 130, 929\u20131941 (2007).","journal-title":"Brain"},{"key":"BFnrneurol201681_CR68","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1172\/JCI41592","volume":"120","author":"KA Orlova","year":"2010","unstructured":"Orlova, K. A.  et al. STRAD\u03b1 deficiency results in aberrant mTORC1 signaling during corticogenesis. J. Clin. Invest. 120, 1591\u20131602 (2010).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201681_CR69","first-page":"182","volume":"24","author":"WE Parker","year":"2013","unstructured":"Parker, W. E.  et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci. Transl. Med. 24, 182\u2013184 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneurol201681_CR70","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ana.24368","volume":"77","author":"S Baulac","year":"2015","unstructured":"Baulac, S.  et al. Familial focal epilepsy with focal cortical dysplasia due to DEPDC mutations. Ann. Neurol. 77, 675\u2013683 (2015).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR71","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.24357","volume":"77","author":"AM D'Gama","year":"2015","unstructured":"D'Gama, A. M.  et al. Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann. Neurol. 77, 720\u2013725 (2015).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/acn3.191","volume":"2","author":"T Scerri","year":"2015","unstructured":"Scerri, T.  et al. Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5. Ann. Clin. Transl. Neurol. 2, 575\u2013580 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"BFnrneurol201681_CR73","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/ana.24502","volume":"79","author":"JC Sim","year":"2016","unstructured":"Sim, J. C.  et al. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3. Ann. Neurol. 79, 132\u2013137 (2016).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR74","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/ana.24547","volume":"79","author":"MG Ricos","year":"2016","unstructured":"Ricos, M. G.  et al. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy. Ann. Neurol. 79, 120\u2013131 (2016).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR75","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.nbd.2016.02.010","volume":"89","author":"E Marsan","year":"2016","unstructured":"Marsan, E.  et al. Depdc5 knockout rat: a novel model of mTORopathy. Neurobiol. Dis. 89, 180\u2013189 (2016).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201681_CR76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nm.3824","volume":"21","author":"JS Lim","year":"2015","unstructured":"Lim, J. S.  et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat. Med. 21, 395\u2013400 (2015).","journal-title":"Nat. Med."},{"key":"BFnrneurol201681_CR77","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ana.24444","volume":"78","author":"M Nakashima","year":"2015","unstructured":"Nakashima, M.  et al. Somatic mutations in the MTOR gene cause focal cortical dysplasia type IIb. Ann. Neurol. 78, 375\u2013386 (2015).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR78","doi-asserted-by":"publisher","first-page":"1237758","DOI":"10.1126\/science.1237758","volume":"34","author":"A Poduri","year":"2013","unstructured":"Poduri, A., Evrony, G. D., Cai, X. & Walsh, C. A. Somatic mutation, genomic variation, and neurological disease. Science 34, 1237758 (2013).","journal-title":"Science"},{"key":"BFnrneurol201681_CR79","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1055\/s-0034-1386764","volume":"34","author":"TW Yu","year":"2014","unstructured":"Yu, T. W. & Berry-Kravis, E. Autism and fragile X syndrome. Semin. Neurol. 34, 258\u2013265 (2014).","journal-title":"Semin. Neurol."},{"key":"BFnrneurol201681_CR80","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","volume":"30","author":"A Sharma","year":"2010","unstructured":"Sharma, A.  et al. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 30, 694\u2013702 (2010).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR81","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","volume":"76","author":"Y Bhattacharya","year":"2012","unstructured":"Bhattacharya, Y.  et al. Genetic removal of p70 S6 kinase corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76, 325\u2013337 (2012).","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR82","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature10658","volume":"480","author":"BD Auerbach","year":"2011","unstructured":"Auerbach, B. D., Osterweil, E. K. & Bear, M. F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63\u201368 (2011).","journal-title":"Nature"},{"key":"BFnrneurol201681_CR83","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2788.2009.01208.x","volume":"53","author":"D Ehninger","year":"2009","unstructured":"Ehninger, D., de Vries, P. J. & Silva, A. J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J. Intellect. Disabil. Res. 53, 838\u2013851 (2009).","journal-title":"J. Intellect. Disabil. Res."},{"key":"BFnrneurol201681_CR84","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nature11310","volume":"488","author":"PT Tsai","year":"2012","unstructured":"Tsai, P. T.  et al. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488, 647\u2013651 (2012). This interesting article demonstrates the role of cerebellar mTOR overactivation in autistic-type traits.","journal-title":"Nature"},{"key":"BFnrneurol201681_CR85","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.brainresbull.2013.11.005","volume":"100","author":"JA Burket","year":"2014","unstructured":"Burket, J. A., Benson, A. D., Tang, A. H. & Deutsch, S. I. Rapamycin improves sociability in the BTBR T+Itpr3tf\/J mouse model of autism spectrum disorders. Brain Res. Bull. 100, 70\u201375 (2014).","journal-title":"Brain Res. Bull."},{"key":"BFnrneurol201681_CR86","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.neuron.2014.07.040","volume":"83","author":"G Tang","year":"2014","unstructured":"Tang, G.  et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83, 1131\u20131143 (2014).","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR87","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","volume":"342","author":"SC Johnson","year":"2013","unstructured":"Johnson, S. C.  et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 342, 1524\u20131528 (2013).","journal-title":"Science"},{"key":"BFnrneurol201681_CR88","doi-asserted-by":"publisher","unstructured":"Zheng, X.  et al. Alleviation of neuronal energy deficiency by mTOR inhibition as a treatment for mitochondria-related neurodegeneration. eLife \n                    http:\/\/dx.doi.org\/10.7554\/eLife.13378\n                    \n                   (2016).","DOI":"10.7554\/eLife.13378"},{"key":"BFnrneurol201681_CR89","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1126\/science.1115535","volume":"310","author":"M Kaeberlein","year":"2005","unstructured":"Kaeberlein, M.  et al. Regulation of yeast replicative life span by mTOR and Sch9 in response to nutrients. Science 310, 1193\u20131196 (2005).","journal-title":"Science"},{"key":"BFnrneurol201681_CR90","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/426620a","volume":"426","author":"T Vellai","year":"2003","unstructured":"Vellai, T.  et al. Genetics: influence of mTOR kinase on lifespan in C. elegans. Nature 426, 620 (2003).","journal-title":"Nature"},{"key":"BFnrneurol201681_CR91","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exger.2014.12.002","volume":"68","author":"A Richardson","year":"2015","unstructured":"Richardson, A., Galvan, V., Lin, A. L. & Oddo, S. How longevity research can lead to therapies for Alzheimer's disease: the rapamycin story. Exp. Gerontol. 68, 51\u201358 (2015).","journal-title":"Exp. Gerontol."},{"key":"BFnrneurol201681_CR92","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2741\/s310","volume":"4","author":"S Oddo","year":"2012","unstructured":"Oddo, S. The role of mTOR signaling in Alzheimer's disease. Front. Biosci. (Schol. Ed.) 4, 941\u2013952 (2012).","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"BFnrneurol201681_CR93","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0002-9440(10)63687-5","volume":"163","author":"WL An","year":"2003","unstructured":"An, W. L.  et al. Up-regulation of phosphorylated\/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 163, 591\u2013607 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol201681_CR94","doi-asserted-by":"publisher","first-page":"27734","DOI":"10.1074\/jbc.M109.008177","volume":"284","author":"T Morita","year":"2009","unstructured":"Morita, T. & Sobue, K. Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR\u2013p70S6K pathway. J. Biol. Chem. 284, 27734\u201327745 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR95","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1074\/jbc.M704292200","volume":"283","author":"V Meske","year":"2008","unstructured":"Meske, V., Albert, F. & Ohm, T. G. Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2A-and glycogen synthase kinase-3-dependent phosphorylation of Tau. J. Biol. Chem. 283, 100\u2013109 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR96","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1471-4159.2004.02949.x","volume":"93","author":"RJ Griffin","year":"2005","unstructured":"Griffin, R. J.  et al. Activation of Akt\/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93, 105\u2013117 (2005).","journal-title":"J. Neurochem."},{"key":"BFnrneurol201681_CR97","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1111\/j.1742-4658.2005.04833.x","volume":"272","author":"X Li","year":"2005","unstructured":"Li, X., Alafuzoff, I., Soininen, H., Winblad, B. & Pei, J. J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 272, 4211\u20134220 (2005).","journal-title":"FEBS J."},{"key":"BFnrneurol201681_CR98","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/NEN.0000000000000083","volume":"73","author":"AM Iyer","year":"2014","unstructured":"Iyer, A. M.  et al. mTOR Hyperactivation in down syndrome hippocampus appears early during development. J. Neuropathol. Exp. Neurol. 73, 671\u2013683 (2014).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrneurol201681_CR99","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3892\/ijmm.2014.1895","volume":"34","author":"J Davies","year":"2014","unstructured":"Davies, J., Zachariades, E., Rogers-Broadway, K. R. & Karteris, E. Elucidating the role of DEPTOR in Alzheimer's disease. Int. J. Mol. Med. 34, 1195\u20131200 (2014).","journal-title":"Int. J. Mol. Med."},{"key":"BFnrneurol201681_CR100","doi-asserted-by":"publisher","first-page":"14042","DOI":"10.1523\/JNEUROSCI.2781-15.2015","volume":"35","author":"A Caccamo","year":"2015","unstructured":"Caccamo, A.  et al. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. J. Neurosci. 35, 14042\u201314056 (2015).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR101","doi-asserted-by":"publisher","first-page":"e0142340","DOI":"10.1371\/journal.pone.0142340","volume":"10","author":"R Siman","year":"2015","unstructured":"Siman, R., Cocca, R. & Dong, Y. The mTOR inhibitor rapamycin mitigates perforant pathway neurodegeneration and synapse loss in a mouse model of early-stage Alzheimer-type tauopathy. PLoS ONE 10, e0142340 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201681_CR102","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3233\/JAD-142097","volume":"44","author":"C Frederick","year":"2015","unstructured":"Frederick, C.  et al. Rapamycin ester analog CCI-779\/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. J. Alzheimers Dis. 44, 1145\u20131156 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol201681_CR103","first-page":"25","volume":"12","author":"P Anglade","year":"1997","unstructured":"Anglade, P.  et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25\u201331 (1997).","journal-title":"Histol. Histopathol."},{"key":"BFnrneurol201681_CR104","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. \u03b1-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009\u201325013 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR105","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer, B.  et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in \u03b1-synuclein models of Parkinson's and Lewy body diseases. J. Neurosci. 29, 13578\u201313588 (2009).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR106","doi-asserted-by":"publisher","first-page":"18757","DOI":"10.1073\/pnas.0606401103","volume":"103","author":"V Ries","year":"2006","unstructured":"Ries, V.  et al. Oncoprotein Akt\/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl Acad. Sci. USA 103, 18757\u201318762 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201681_CR107","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1523\/JNEUROSCI.5519-10.2011","volume":"31","author":"HC Cheng","year":"2011","unstructured":"Cheng, H. C.  et al. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J. Neurosci. 31, 2125\u20132135 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR108","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/hmg\/11.9.1107","volume":"11","author":"B Ravikumar","year":"2002","unstructured":"Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107\u20131117 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrneurol201681_CR109","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar, B.  et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585\u2013595 (2004).","journal-title":"Nat. Genet."},{"key":"BFnrneurol201681_CR110","doi-asserted-by":"publisher","first-page":"ra103","DOI":"10.1126\/scisignal.2005633","volume":"7","author":"WM Pryor","year":"2014","unstructured":"Pryor, W. M.  et al. Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease. Sci. Signal. 7, ra103 (2014).","journal-title":"Sci. Signal."},{"key":"BFnrneurol201681_CR111","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1083\/jcb.200504035","volume":"170","author":"S Sarkar","year":"2005","unstructured":"Sarkar, S.  et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101\u20131111 (2005).","journal-title":"J. Cell Biol."},{"key":"BFnrneurol201681_CR112","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1074\/jbc.M609532200","volume":"2282","author":"S Sarkar","year":"2007","unstructured":"Sarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A. & Rubinsztein, D. C. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and \u03b1-synuclein. J. Biol. Chem. 2282, 5641\u20135652 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR113","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ncb3101","volume":"17","author":"YN Rui","year":"2015","unstructured":"Rui, Y. N.  et al. Huntingtin functions as a scaffold for selective macroautophagy. Nat. Cell Biol. 17, 262\u2013275 (2015).","journal-title":"Nat. Cell Biol."},{"key":"BFnrneurol201681_CR114","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.neuropharm.2010.10.025","volume":"60","author":"S Subramaniam","year":"2011","unstructured":"Subramaniam, S. & Snyder, S. H. Huntington's disease is a disorder of the corpus striatum: focus on Rhes (Ras homologue enriched in the striatum). Neuropharmacology 60, 1187\u20131192 (2011).","journal-title":"Neuropharmacology"},{"key":"BFnrneurol201681_CR115","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1074\/jbc.M113.536912","volume":"289","author":"RG Mealer","year":"2014","unstructured":"Mealer, R. G., Murray, A. J., Shahani, N., Subramaniam, S. & Snyder, S. H. Rhes, a striatal-selective protein implicated in Huntington disease, binds beclin-1 and activates autophagy. J. Biol. Chem. 289, 3547\u20133554 (2014).","journal-title":"J. Biol. Chem."},{"key":"BFnrneurol201681_CR116","doi-asserted-by":"publisher","first-page":"16982","DOI":"10.1073\/pnas.1004498107","volume":"107","author":"AS Tsvetkov","year":"2010","unstructured":"Tsvetkov, A. S.  et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc. Natl Acad. Sci. USA 107, 16982\u201316987 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201681_CR117","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.neuron.2014.12.019","volume":"85","author":"JH Lee","year":"2015","unstructured":"Lee, J. H.  et al. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. Neuron 85, 303\u2013315 (2015).","journal-title":"Neuron"},{"key":"BFnrneurol201681_CR118","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2174\/1567202611666140408104831","volume":"11","author":"K Maiese","year":"2014","unstructured":"Maiese, K. Cutting through the complexities of mTOR for the treatment of stroke. Curr. Neurovasc. Res. 11, 177\u2013186 (2014).","journal-title":"Curr. Neurovasc. Res."},{"key":"BFnrneurol201681_CR119","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.cellsig.2013.03.017","volume":"25","author":"ZZ Chong","year":"2013","unstructured":"Chong, Z. Z., Yao, Q. & Li, H. H. The rationale of targeting mammalian target of rapamycin for ischemic stroke. Cell. Signal. 25, 1598\u20131607 (2013).","journal-title":"Cell. Signal."},{"key":"BFnrneurol201681_CR120","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neulet.2011.11.058","volume":"507","author":"H Chen","year":"2012","unstructured":"Chen, H.  et al. mTOR activates hypoxia-inducible factor-1\u03b1 and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Neurosci. Lett. 507, 118\u2013123 (2012).","journal-title":"Neurosci. Lett."},{"key":"BFnrneurol201681_CR121","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4161\/auto.6.3.11261","volume":"6","author":"S Carloni","year":"2010","unstructured":"Carloni, S.  et al. Activation of autophagy and Akt\/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. Autophagy 6, 366\u2013377 (2010).","journal-title":"Autophagy"},{"key":"BFnrneurol201681_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2014.01.017","volume":"1553","author":"T Urbanek","year":"2014","unstructured":"Urbanek, T., Kuczmik, W., Basta-Kaim, A. & Gabryel, B. Rapamycin induces of protective autophagy in vascular endothelial cells exposed to oxygen-glucose deprivation. Brain Res. 1553, 1\u201311 (2014).","journal-title":"Brain Res."},{"key":"BFnrneurol201681_CR123","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1161\/STROKEAHA.114.005406","volume":"45","author":"R Xie","year":"2014","unstructured":"Xie, R.  et al. Mammalian target of rapamycin cell signaling pathway contributes to the protective effects of ischemic postconditioning against stroke. Stroke 45, 2769\u20132776 (2014).","journal-title":"Stroke"},{"key":"BFnrneurol201681_CR124","doi-asserted-by":"publisher","first-page":"e68281","DOI":"10.1371\/journal.pone.0068281","volume":"8","author":"L Fletcher","year":"2013","unstructured":"Fletcher, L., Evans, T. M., Watts, L. T., Jimenez, D. F. & Digicaylioglu, M. Rapamycin treatment improves neuron viability in an in vitro model of stroke. PLoS ONE 8, e68281 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201681_CR125","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3109\/00207454.2012.721827","volume":"122","author":"L Yin","year":"2012","unstructured":"Yin, L., Ye, S., Chen, Z. & Zeng, Y. Rapamycin preconditioning attenuates transient focal cerebral ischemia\/reperfusion injury in mice. Int. J. Neurosci. 122, 748\u2013756 (2012).","journal-title":"Int. J. Neurosci."},{"key":"BFnrneurol201681_CR126","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nbd.2014.02.006","volume":"66","author":"X Xiong","year":"2014","unstructured":"Xiong, X.  et al. PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways. Neurobiol. Dis. 66, 43\u201352 (2014).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201681_CR127","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/jcbfm.2013.132","volume":"33","author":"R Xie","year":"2013","unstructured":"Xie, R.  et al. Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities. J. Cereb. Blood Flow Metab. 33, 1875\u20131885 (2013).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrneurol201681_CR128","doi-asserted-by":"publisher","first-page":"ra11","DOI":"10.1126\/scisignal.2000143","volume":"2","author":"CY Wang","year":"2009","unstructured":"Wang, C. Y.  et al. Obesity increases vascular senescence and susceptibility in ischemic injury through chronic activation of Akt and mTOR. Sci. Signal. 2, ra11 (2009).","journal-title":"Sci. Signal."},{"key":"BFnrneurol201681_CR129","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1742-2094-11-44","volume":"11","author":"Q Luo","year":"2014","unstructured":"Luo, Q.  et al. Inhibition of mammalian target of rapamycin improves neurobehavioral deficit and modulates immune response after intracerebral hemorrhage in rat. J. Neuroinflamm. 11, 44\u201347 (2014).","journal-title":"J. Neuroinflamm."},{"key":"BFnrneurol201681_CR130","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nbd.2015.10.001","volume":"85","author":"IN Srivastava","year":"2016","unstructured":"Srivastava, I. N., Shperdheja, J., Baybis, M., Ferguson, T. & Crino, P. B. mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy. Neurobiol. Dis. 85, 144\u2013154 (2016).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201681_CR131","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.drudis.2012.04.010","volume":"17","author":"AS Don","year":"2012","unstructured":"Don, A. S.  et al. Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov. Today 17, 861\u2013868 (2012).","journal-title":"Drug Discov. Today"},{"key":"BFnrneurol201681_CR132","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.jcbfm.9600393","volume":"27","author":"S Chen","year":"2007","unstructured":"Chen, S.  et al. Alterations in mammalian target of rapamycin signaling pathways after traumatic brain injury. J. Cereb. Blood Flow Metab. 27, 939\u2013949 (2007).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrneurol201681_CR133","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nbd.2006.12.003","volume":"26","author":"S Erlich","year":"2007","unstructured":"Erlich, S., Alexandrovich, A., Shohami, E. & Pinkas-Kramarski, R. Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol. Dis. 26, 86\u201393 (2007).","journal-title":"Neurobiol. Dis."},{"key":"BFnrneurol201681_CR134","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1089\/neu.2015.3899","volume":"33","author":"I Nikolaeva","year":"2016","unstructured":"Nikolaeva, I., Crowell, B., Valenziano, J., Meaney, D. & D'Arcangelo, G. Beneficial effects of early mTORC1 inhibition after traumatic brain injury. J. Neurotrauma 33, 183\u2013193 (2016).","journal-title":"J. Neurotrauma"},{"key":"BFnrneurol201681_CR135","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1523\/JNEUROSCI.3870-12.2013","volume":"33","author":"Y Berdichevsky","year":"2013","unstructured":"Berdichevsky, Y.  et al. PI3K\u2013Akt signaling activates mTOR-mediated epileptogenesis in organotypic hippocampal culture model of post-traumatic epilepsy. J. Neurosci. 33, 9056\u20139067 (2013).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201681_CR136","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/neuonc\/noq052","volume":"12","author":"D Akhavan","year":"2010","unstructured":"Akhavan, D., Cloughesy, T. F. & Mischel, P. S. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 12, 882\u2013889 (2010).","journal-title":"Neuro Oncol."},{"key":"BFnrneurol201681_CR137","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/neuonc\/nou164","volume":"17","author":"D Pachow","year":"2015","unstructured":"Pachow, D., Wick, W., Gutman, D. H. & Mawrin, C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol. 17, 189\u2013199 (2015).","journal-title":"Neuro Oncol."},{"key":"BFnrneurol201681_CR138","first-page":"2742","volume":"63","author":"G Choe","year":"2003","unstructured":"Choe, G.  et al. Analysis of the phosphatidylinositol 3\u2032-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742\u20132746 (2003).","journal-title":"Cancer Res."},{"key":"BFnrneurol201681_CR139","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1593\/neo.04595","volume":"7","author":"X Hu","year":"2005","unstructured":"Hu, X.  et al. mTOR promotes survival and astrocytic characteristics induced by Pten\/AKT signaling in glioblastoma. Neoplasia 7, 356\u2013368 (2005).","journal-title":"Neoplasia"},{"key":"BFnrneurol201681_CR140","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/0008-5472.CAN-07-2223","volume":"67","author":"J Masri","year":"2007","unstructured":"Masri, J.  et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67, 1712\u201311720 (2007).","journal-title":"Cancer Res."},{"key":"BFnrneurol201681_CR141","doi-asserted-by":"publisher","first-page":"e47741","DOI":"10.1371\/journal.pone.0047741","volume":"7","author":"T Bashir","year":"2012","unstructured":"Bashir, T.  et al. Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS ONE 7, e47741 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201681_CR142","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1528-1167.2007.00925.x","volume":"48","author":"U Samadani","year":"2007","unstructured":"Samadani, U., Judkins, A. R., Akpalu, A., Aronica, E. & Crino, P. B. Differential cellular gene expression in ganglioglioma. Epilepsia 48, 646\u2013653 (2007).","journal-title":"Epilepsia"},{"key":"BFnrneurol201681_CR143","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1750-3639.2009.00268.x","volume":"20","author":"K Boer","year":"2010","unstructured":"Boer, K.  et al. Pi3K\u2013mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol. 20, 234\u2013244 (2010).","journal-title":"Brain Pathol."},{"key":"BFnrneurol201681_CR144","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng.2526","volume":"45","author":"PK Brastianos","year":"2013","unstructured":"Brastianos, P. K.  et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285\u2013289 (2013).","journal-title":"Nat. Genet."},{"key":"BFnrneurol201681_CR145","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","volume":"19","author":"D Pachow","year":"2013","unstructured":"Pachow, D.  et al. mTORC1 inhibitors suppress meningioma growth in mouse models. Clin. Cancer Res. 19, 1180\u20131189 (2013).","journal-title":"Clin. Cancer Res."},{"key":"BFnrneurol201681_CR146","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis, E.  et al. Phase II trial of temsirolimus (CCi-779) in recurrent glioblastomamultiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294\u20135304 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrneurol201681_CR147","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/nou328","volume":"17","author":"DJ Ma","year":"2015","unstructured":"Ma, D. J.  et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 17, 1261\u20131269 (2015).","journal-title":"Neuro Oncol."},{"key":"BFnrneurol201681_CR148","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/not247","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen, P. Y.  et al. Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04\u201302. Neuro Oncol. 16, 567\u2013578 (2014).","journal-title":"Neuro Oncol."},{"key":"BFnrneurol201681_CR149","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.ijrobp.2013.04.036","volume":"86","author":"P Chinnaiyan","year":"2013","unstructured":"Chinnaiyan, P.  et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 86, 880\u2013884 (2013).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrneurol201681_CR150","first-page":"240","volume":"10","author":"JD Hainsworth","year":"2012","unstructured":"Hainsworth, J. D.  et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab\/everolimus as a first-line treatment for patients with glioblastoma. Clin. Adv. Hematol. Oncol. 10, 240\u2013246 (2012).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"BFnrneurol201681_CR151","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijrobp.2010.05.064","volume":"81","author":"JN Sarkaria","year":"2011","unstructured":"Sarkaria, J. N.  et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 81, 468\u2013475 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrneurol201681_CR152","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-008-9741-z","volume":"92","author":"TN Kreisl","year":"2009","unstructured":"Kreisl, T. N.  et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol. 92, 99\u2013105 (2009).","journal-title":"J. Neurooncol."},{"key":"BFnrneurol201681_CR153","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1212\/01.wnl.0000223844.77636.29","volume":"67","author":"L Doherty","year":"2006","unstructured":"Doherty, L.  et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67, 156\u2013158 (2006).","journal-title":"Neurology"},{"key":"BFnrneurol201681_CR154","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","volume":"363","author":"DA Krueger","year":"2010","unstructured":"Krueger, D. A.  et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801\u20131811 (2010). The first study to demonstrate clinical success of mTOR inhibition with everolimus in tuberous sclerosis complex.","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201681_CR155","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00381-010-1222-y","volume":"27","author":"M Yalon","year":"2011","unstructured":"Yalon, M., Ben-Sira, L., Constantini, S. & Toren, A. Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex. Childs Nerv. Syst. 27, 179\u2013181 (2011).","journal-title":"Childs Nerv. Syst."},{"key":"BFnrneurol201681_CR156","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","volume":"80","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A.  et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80, 574\u2013580 (2013).","journal-title":"Neurology"},{"key":"BFnrneurol201681_CR157","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/ana.24523","volume":"78","author":"DN Franz","year":"2015","unstructured":"Franz, D. N.  et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann. Neurol. 78, 929\u2013938 (2015).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR158","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1212\/WNL.0b013e318247ca8d","volume":"78","author":"JM Tillema","year":"2012","unstructured":"Tillema, J. M., Leach, J. L., Krueger, D. A. & Franz, D. N. Everolimus alters white matter in tuberous sclerosis complex. Neurology 78, 526\u2013531 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol201681_CR159","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ana.23960","volume":"74","author":"DA Krueger","year":"2013","unstructured":"Krueger, D. A.  et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. 74, 679\u2013687 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR160","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ebcr.2015.06.008","volume":"4","author":"JW Wheless","year":"2015","unstructured":"Wheless, J. W. Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy. Epilepsy Behav. Case Rep. 4, 63\u201366 (2015).","journal-title":"Epilepsy Behav. Case Rep."},{"key":"BFnrneurol201681_CR161","first-page":"129","volume":"45","author":"A Wiemer-Kruel","year":"2014","unstructured":"Wiemer-Kruel, A., Woerle, H., Strobl, K. & Bast, T. Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report. Neuropediatrics 45, 129\u2013131 (2014).","journal-title":"Neuropediatrics"},{"key":"BFnrneurol201681_CR162","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.21331","volume":"63","author":"LH Zeng","year":"2008","unstructured":"Zeng, L. H., Xu, L., Gutmann, D. H. & Wong, M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann. Neurol. 63, 444\u2013453 (2008). This important study was the first to show a benefit of mTOR inhibitors in a mouse model of tuberous sclerosis complex.","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201681_CR163","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1586\/ern.13.49","volume":"13","author":"P Curatolo","year":"2013","unstructured":"Curatolo, P. & Moavero, R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev. Neurother. 13, 627\u2013638 (2013).","journal-title":"Expert Rev. Neurother."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.81","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:20:24Z","timestamp":1684455624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2016.81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":163,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFnrneurol201681"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2016.81","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726447263.793531900","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]},"assertion":[{"value":"24 June 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}